Lund, Sweden - 21 May 2026 - Camurus (NASDAQ STO: CAMX) will participate in the Jefferies Global Healthcare Conference in New York, 2-4 June, 2026. President and CEO Fredrik Tiberg will present on 3 June at 10.55 pm CET, providing an update on the company's recent developments.
A webcast of the presentation will be available through the following link:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=iX2ZMLifXKSubp3gHo3gjg
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information was submitted for publication at 10:00 am CET on 21 May 2026.